Clinical immunology<br>Serum levels of interleukin 17 and its activators in chronic hepatitis C patients

Krzysztof Gutkowski; Marek Hartleb; Teresa Kacperek-Hartleb; Joanna Musialik; Grzegorz Boryczka; Maciej Kajor

doi:10.5114/ceji.2013.34361

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2013
vol. 38

Send email

Copy url:

abstract:

Clinical immunology
Serum levels of interleukin 17 and its activators in chronic hepatitis C patients

Krzysztof Gutkowski

,

Marek Hartleb

,

Teresa Kacperek-Hartleb

,

Joanna Musialik

,

Grzegorz Boryczka

,

Maciej Kajor

(Centr Eur J Immunol 2013; 38 (1): 76-79)

DOI: https://doi.org/10.5114/ceji.2013.34361

Online publish date: 2013/04/17

View full text Get citation

PlumX metrics:

Immune dysregulations in patients with chronic hepatitis C are still poorly understood, particularly their inflammatory pathways. Recent studies have shown that transforming growth factor β (TGF-β) alone promotes the generation of anti-inflammatory regulatory T lymphocytes (T-reg) from nal¨ve T CD4+ cells, while TGF-β in concert with interleukin 6 (IL-6) promotes Th17 cells that produce IL-17. We studied serum levels of IL-17 and its known activators (IL-6, TGF-β) in 55 hepatitis C patients and 33 age- and gender-matched healthy subjects. Cytokine levels were quantified by sandwich enzyme-linked immunosorbent assays. Surprisingly, IL-17 serum levels were significantly higher in healthy subjects than in hepatitis C patients (16.5 ±6.6 pg/ml vs. 8.1 ±5.5 pg/ml; p < 0.0000). By contrast, serum

TGF-β levels were significantly lower in healthy subjects (30.9 ±7.4 ng/ml vs. 40.7 ±20.6 ng/ml; p = 0.0327). Serum levels of IL-6 did not differ between groups but correlated positively with the stage of fibrosis in hepatitis C patients (r = 0.36; p = 0.005). Our findings suggest that hepatitis C virus down-regulates IL-17 production and up-regulates TGF-β production. The increased level of TGF-β in HCV patients may be responsible for suppressing IL-17 production by Th17 cells.

keywords:

Clinical immunologySerum levels of interleukin 17 and its activators in chronic hepatitis C patients

Krzysztof Gutkowski , Marek Hartleb , Teresa Kacperek-Hartleb , Joanna Musialik , Grzegorz Boryczka , Maciej Kajor

hepatitis C, interleukin 17, TGF-β

Clinical immunology
Serum levels of interleukin 17 and its activators in chronic hepatitis C patients

Krzysztof Gutkowski

,

Marek Hartleb

,

Teresa Kacperek-Hartleb

,

Joanna Musialik

,

Grzegorz Boryczka

,

Maciej Kajor